Mutation protects from HIV - and increases risk of hepatitis CJuly 17, 2002More than 40 million people worldwide are infected with the human immunodeficiency virus HIV. In Africa alone this incurable immune deficiency caused more than two million deaths last year. Yet some people are resistant to infection: the reason for this is a mutation in their DNA which prevents the HIV virus from invading certain immune cells and destroying them. Bonn scientists have now discovered, however, that this resistance to HIV increases the probability of a persistent infection with hepatitis C, a disease which can also be fatal. The findings recently published in the journal Gastroenterology may have influence on possible therapeutic strategies for tackling HIV infections. When a hepatitis C virus infects a liver cell, the cell secretes so-called chemokines into the blood. Chemokines are signal substances which normally attract inflammatory cells. These "T-lymphocytes" kill the infected cell and in doing so also kill the viruses which have caused the infection. T-lymphocytes have a sensor for chemokines on their surface. However, this sensor does not work in some humans: due to a mutation, their cells cannot express a functional sensor on the cell surface. Thus, a liver cell`s cry for help is not answered because the immune cells are blind and deaf to virus attacks. Therefore the body obviously finds it difficult to defend itself against other infections like hepatitis C. However, the same mutation also prevents this person from contracting HIV infections: AIDS viruses, among other things, infect T-lymphocytes, put them out of action and in doing so cause the fatal immune deficiency which gave the disease its name. Most HIV strains enter the cells using the chemokine sensor as a 'gateway'. If it is altered, the virus cannot invade the immune cell. Every cell has two copies of the sensor gene - one from the mother, one from the father. In people who have one mutated copy, HIV infection takes a less progressive course of disease. If both copies are mutated, the person affected is resistant to most HIV strains. About one per cent of the German population has inherited two defective sensor genes. Among patients infected with the hepatitis C virus this percentage is markedly higher: 'Twelve people out of 153 with hepatitis C anti-bodies had two copies of the mutated gene,' Professor Ulrich Spengler from the Medical Clinic and Policlinic I explains. This is the equivalent to 7.8 per cent, which is much higher than would be statistically expected. 'The amount of viruses found in these patients` blood was up to four times as high as with hepatitis C patients without this mutation.' The result indicates that the mutation facilitates to establish persistent infection by the viruses causing hepatitis. 'A powerful immune response is especially important in the early phase of a hepatitis C infection,' Professor Spengler explains: the more effective the immune system works in this 'acute phase', the more likely it is that the body will cope with the virus attack. Otherwise there is a risk of the hepatitis becoming chronic. The after-effects of this can involve scarring of this vital organ. The circulation of blood through a 'cirrhotic' liver is sometimes so difficult that, for example, the blood vessels inside the oesophagus may become pathologically distended and burst during food intake. Apart from that there is a substantially higher risk of liver cancer in cases of chronic hepatitis C. There are around 150 million hepatitis C patients worldwide. One in 200 Germans are infected with the dangerous virus. In three quarters of those affected the disease becomes chronic - probably because their immune system was not sufficiently effective in the early phase. 'We do not know what exactly determines whether the body's defence is successful,' Professor Spengler admits, 'however, in some cases the mutation of the chemokine sensor gene seems to play an important part.' Possible defence strategies against AIDS which are based on interfering with the chemokine sensors could therefore have drastic side-effects - 'a risk which definitely needs to be considered as part of further research.' | |||||||||||||||||||||
|
Related HIV Current Events and HIV News Articles Study sheds light on causes of HIV dementia A new study led by researchers at Albert Einstein College of Medicine of Yeshiva University has clarified how two major variants of HIV differ in their ability to cause neurologic complications. New HIV film tackles stigma faced by teachers in Africa Addressing the discrimination against HIV-positive teachers in Africa is a key aim of a new documentary and accompanying book being launched in Senegal today by the Partnership for Child Development based at Imperial College London. Selenium may slow march of AIDS Increasing the production of naturally occurring proteins that contain selenium in human blood cells slows down multiplication of the AIDS virus, according to biochemists. ACP recommends routine HIV screening for all patients On World AIDS Day, the American College of Physicians (ACP) is giving doctors a call-to-action to routinely encourage HIV screening to all of their patients older than 13 years. This new practice guideline appears on the Annals of Internal Medicine Web site at www.annals.org. Study of ancient and modern plagues finds common features In 430 B.C., a new and deadly disease-its cause remains a mystery-swept into Athens. The walled Greek city-state was teeming with citizens, soldiers and refugees of the war then raging between Athens and Sparta. Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents. More at-risk teens and young adults engaging in anal intercourse A new study by researchers at the Bradley Hasbro Children's Research Center suggests that the incidence of heterosexual anal sex is increasing among teens and young adults - particularly those who have recently had unprotected vaginal sex. Landmark study defines benefits of early HIV testing and treatment for infected infants Testing very young babies for HIV and giving antiretroviral therapy (ART) immediately to those found infected with the virus dramatically prevents illness and death, according to a report in the New England Journal of Medicine. Stopping germs from ganging up on humans Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson. More HIV Current Events and HIV News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||